The 2017 meeting will again include representatives from academia, the National Institutes of Health (NIH), Food and Drug Administration (FDA), European regulatory agencies and industry to discuss key aspects of neuropsychiatric drug development, including the impact of diagnostic changes and personalized interventions based on biomarkers or genetic information. A Steering Committee chaired by Drs. Marlene Freeman and John Newcomer with representation of the sectors that are part of the ASCP community will lead the direction of the meeting. Representatives from the FDA, EMA, NIMH, NIDA, NIAAA, and academia comprise the 2017 Steering Committee. A Program Committee under the leadership of Drs. Holly Swartz and Alan Gelenberg will be responsible for review of all program submissions.
2016 ASCP Annual Meeting Submission Deadlines: